Coming of age: the use of immunomodulatory therapy in children with multiple sclerosis.
Banwell
Brenda
B
Tremlett
Helen
H
D000367:Age Factors; D000375:Aging / Q000187:drug effects / Q000502:physiology; D002490:Central Nervous System / Q000187:drug effects* / Q000276:immunology* / Q000503:physiopathology; D002648:Child; D002986:Clinical Trials as Topic / Q000592:standards / Q000706:statistics & numerical data; D018450:Disease Progression; D004345:Drug Industry / Q000191:economics / Q000592:standards / Q000639:trends; D000068717:Glatiramer Acetate; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology* / Q000627:therapeutic use*; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology* / Q000503:physiopathology; D010455:Peptides / Q000494:pharmacology / Q000627:therapeutic use; D055502:Secondary Prevention; D011795:Surveys and Questionnaires / Q000592:standards; D016896:Treatment Outcome
D007155:Immunologic Factors; D010455:Peptides; D000068717:Glatiramer Acetate; D016899:Interferon-beta; D000068556:Interferon beta-1a